

**PCT**WORLD INTELLECTUAL  
PROPERTY ORGANIZATION

WO 9602666A1

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12Q 1/04, 1/06, G01N 33/569, 33/543,</b> <b>C12Q 1/48, 1/66</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/02666</b> <b>(43) International Publication Date:</b> 1 February 1996 (01.02.96)
<b>(21) International Application Number:</b> PCT/GB95/01643 <b>(22) International Filing Date:</b> 12 July 1995 (12.07.95) <b>(30) Priority Data:</b> 9414096.9 13 July 1994 (13.07.94) GB <b>(71) Applicant (for all designated States except US):</b> THE SECRETARY OF STATE FOR DEFENCE [GB/GB]; Defence Evaluation & Research Agency, DRA Farnborough, Hampshire GU14 6TD (GB). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> SQUIRRELL, David, James [GB/GB]; CBDE, Ministry of Defence, Porton Down, Salisbury, Wiltshire SP4 0JQ (GB). <b>(74) Agent:</b> BECKHAM, Robert, William; Defence Evaluation & Research Agency, Intellectual Property Dept., R69 Building, DRA Farnborough, Hampshire GU14 6TD (GB).		<b>(81) Designated States:</b> AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>

**(54) Title:** CAPTURE ASSAYS**(57) Abstract**

A method is provided for determining the presence and/or amount of a microorganism and/or its intracellular material present in a sample characterised in that:(a) exposing the sample to a specific binding agent that has been immobilised upon a solid substrate, the specific binding agent being capable of binding to the microorganism or its intracellular material such that it becomes associated with the solid substrate, (b) exposing the solid substrate to an agent capable of making adenylate kinase associated with the microorganism and/or its intracellular material accessible to solutions applied to the substrate, (c) applying a solution containing adenosine diphosphate (ADP) to the substrate under conditions whereby adenosine triphosphate (ATP) may be produced by any adenylate kinase present, and (d) measuring the amount of adenosine triphosphate (ATP) and relating that to the presence and/or amount of microorganism or intracellular contents. Step (d) may be carried out using an assay that includes a colour forming reaction, but is preferably carried out by use of luciferase/luciferin reagent to produce light proportional to the amount of ATP produced, and that is detected using a luminometer. Preferably step (c) includes presence of magnesium ions at a molar concentration sufficient to allow maximal conversion of ADP to ATP. Most preferably step (b) and (c) are carried out by adding extractant, ADP and magnesium ions to the sample and incubating the mixture for a predetermined period to effect conversion of ADP to ATP.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## CAPTURE ASSAYS

The present invention relates to a method for detecting and assaying micro-organisms, to reagents for use in such a method, and to test kits comprising essential reagents for carrying out the method.

All living organisms utilise adenosine triphosphate (ATP) as a source of chemical energy and it is known to assay this using the ATP driven luciferase/luciferin reaction. Light generated by this enzymic reaction can be measured using a luminometer and related to the amount of ATP present. The usefulness of ATP as an index of microbial numbers has been known since the mid 1960's (see ATP Luminescence Rapid Methods in Microbiology (1989) editor Stanley et al: Blackwell Scientific Publications, London, see pages 1-10); its main advantage being speed and sensitivity. Utilising this assay format simple samples can be analysed in a matter of minutes while complex ones routinely take only half an hour with a detection capability provided down to  $10^{-12}$  mol/l ATP. There is however a need for methods, which provide still further sensitivity when detecting micro-organisms or their contents while retaining speed and ease of performance.

The present inventor has determined that the speed and sensitivity of ATP based methods can be enhanced significantly by shifting the target of the assay from ATP to an enzyme which generates it, particularly to adenylate kinase. Adenylate kinase is an enzyme used by all organisms for the interconversion of adenosine diphosphate (ADP), adenosine triphosphate (ATP) and adenosine monophosphate (AMP). The targeting of this enzyme in preference to ATP, by using the preferred method, reagents and kits of the invention, allows the detection of down to at least  $10^{-20}$  moles of intracellular marker adenylate kinase.

It is known to assay adenylate kinase using the luciferase/luciferin system (see Brolin et al Journal of Biochemical and Biophysical Methods 1 (1979) 163-169 and Shutenko et al. Biotechnologiya, No 4, (1988) 542-547) for the purpose of determining its activity and this has been applied to study of certain mammalian and plant tissues (eg see Rodionova et al Fiziologiya Rastenii (1978) 25, 4, P731-734). The use of such assay system for the detection

and assay of micro-organisms however has not been suggested and the advantages of doing such, ie enhanced sensitivity so provided, have not been relevant to those studying the enzyme itself.

Although adenylate kinase is present in smaller quantities than ADP, its use as a biological marker for micro-organisms provides enhanced sensitivity with a typical amplification available of 400,000 by measuring its presence through the ATP it produces: that is for every mole of enzyme present 400,000 moles of ADP are converted to ATP in a 10 minute incubation. Thus estimation of the enzyme by measuring the substrate or product of the reaction it catalyses provides for detection down to as low as  $10^{-20}$  moles.

The applicant's copending PCT applications PCT/GB94/00118 and PCT/GB94/-our ref 1GP0036WOD, relate to methods of estimation of micro-organisms in a sample from its ability to convert ADP to ATP, and relating that to the presence of micro-organisms or their intracellular materials. These applications exemplify methods where magnesium ions, necessary for the reaction of ADP with adenylate kinase, are either added as a reagent or provided by any bacteria cells present and as an impurity in the other reagents. The number of cells detected in the examples using such technique proved to be about  $10^2$ , with results of a more statistically valid nature being obtained at  $10^3$  or more; a linear relationship between luminometry counts and cell numbers then being obtainable.

The present invention relates to an improved technique in which adenylate kinase activity is used as a label or marker for micro-organisms in a capture assay, wherein once the micro-organism has been captured and other reagents removed, that number of micro-organisms so captured is determined by making their intracellular contents accessible to ADP, and then measuring the amount of ATP produced, particularly by measuring light produced on performance of the luciferin/luciferase reaction as this provides rapid measurement capability. It will be realised that colorimetric methods for determining the amount of ATP present in a sample may also be used where that is desired, eg using pyruvate kinase based reactions: such colorimetric assay linked to the adenylate kinase assay providing excellent sensitivity.

The micro-organisms may be captured by any conventional capture assay, eg by use of antibodies specific thereto which have been immobilised onto a solid surface, eg a microtitre well plate or latex bead. Many alternative surfaces suitable for immunoassays will occur to those skilled in the art. Particularly preferred in the present method is immobilising the antibodies upon magnetic beads whereupon any micro-organisms bound to the antibodies may be captured within a magnetic field, their adenylate kinase activity assessed, and then released such that a further sample of test material may be analysed. Thus in such a preferred method continuous flow assay of a sample, eg derived from a continuous source such as cyclone sampler monitoring air bacterial content, may be carried out.

Using the adenylate kinase assay format, particularly with adenylate kinase and ATP depleted reagents, the number of micro-organisms present in a sample that can be detected on-line in continuous fashion is of the order of tens per 200 $\mu$ l sample, and readings with quantitative relation between cells and ATP derived light are possible down to 10 cells and even fewer than 10 as the reaction volume is reduced.

Thus in a first aspect of the present invention there is provided a method for determining the presence and/or amount of a micro-organism and/or its intracellular material present in a sample characterised in that:

- (a) the sample is exposed to a specific binding agent that has been immobilised upon a solid substrate, the specific binding agent being capable of binding to the micro-organism or its intracellular material such that it becomes associated with the solid substrate;
- (b) exposing the solid substrate to an agent capable of making adenylate kinase associated with the micro-organism and/or its intracellular material accessible to solutions applied to the substrate;
- (c) applying a solution containing adenosine diphosphate (ADP) to the substrate;

- (d) measuring the amount of adenosine triphosphate (ATP) produced and relating that to the presence and/or amount of micro-organism or intracellular contents.

The step (d) may be carried out using any of the convenient assays available for assay of ATP. Conveniently these may include a colour forming reaction, but most preferably widely available luciferin/luciferase luminescence reagents are used to detect the conversion of ADP to ATP as will be known by those skilled in the art. The relation of the amount of ATP to the amount of micro-organism and/or intracellular content is readily performed by use of calibration curves prepared by performing the assay method using known amounts of target micro-organism or intracellular material and estimating the unknown amount by comparison with this. For the preferred method a calibration curve of light emitted per number of micro-organisms will be prepared, and a reading of light output per unit time from an unknown amount of material in a sample interpreted from that.

In order to maximise the amount of ATP produced, and thus the amplification of the amount of adenylate kinase associated with the solid substrate in the assay the conversion of ADP to ATP is preferably carried out in the presence of magnesium ions at a molar concentration sufficient to allow maximal conversion of ADP to ATP. The amount of magnesium present is preferably such that there is sufficient to provide approximately one mole of magnesium for one mole of ADP such that all of the ADP molecules may be associated with at least one magnesium ion. Note that the reaction is  $\text{ADP} + \text{Mg}^{2+} \rightleftharpoons \text{Mg}^{2+} \cdot \text{ADP} \rightleftharpoons \text{Mg}^{2+} \cdot \text{ATP} + \text{AMP}$  therefore a 1:1 ratio is not actually necessary, however it is a useful guide.

In preferred embodiments of this aspect of the invention the sample is provided in the form of an aqueous suspension or solution, any target micro-organisms or materials in the sample captured, and the estimation of adenylate kinase associated therewith is carried out by adding ADP and magnesium ions to the sample under conditions whereby any adenylate kinase present will convert ADP to ATP, the sample incubated for a predetermined period to effect

such conversion, luciferase and luciferin agents added, the amount of light emitted from the sample determined and related to presence and amount of adenylate kinase.

The capture step is preferably carried out using immobilised antibodies which are specific to a genus, species or class of micro-organism, but may be binding agents specific to particular materials on the cell walls of many different types of micro-organism, eg agents such as lectins. Most conveniently the capture agent will be an antibody and it will be linked to the solid substrate using conventional binding techniques, for example using covalent coupling or streptavidin/biotin interaction. For example, biotinylation of the specific antibody renders it bindable to streptavidin coated surfaces.

In a preferred method magnetic solid substrate is used, particularly magnetic beads such as those available from Dynal UK Ltd, Station House, 26 Grove Street, New Ferry, Wirral, Merseyside. Methods for binding specific antibodies to these beads will be known to those skilled in the art and discussed in the manufacturer's literature.

Use of such beads allows the target micro-organism to be bound to the bead immobilised antibodies in a solution, including that passing down a conduit such as in a continuous sampling apparatus, to be collected at a treatment station by application of a magnetic field, treated to render adenylate kinase accessible while ADP and ATP measuring assay reagents are supplied. Preferably ADP, magnesium and luciferase/luciferin reagents are added while the beads are immobilised and light emitted is measured using a light detector such as a luminometer adjacent the station. The luciferase/luciferin reagents may be added simultaneously with the ADP and magnesium, or subsequently.

The method of the invention may be performed in a single assay vessel by adding magnetic beads with antibody immobilised thereon to the vessel, adding the sample to be assayed as a solution or suspension and stirring it, immobilising the beads with any captured micro-organisms and/or material using a magnetic field, removing residual solution or suspension, adding ADP substrate and extractant solution or solutions for rendering the adenylate kinase accessible to ADP solution, removing the magnetic field and stirring the beads in the

substrate solution, immobilising the beads by reapplication of the magnetic field, removing solution containing the ADP, extractant and any ATP formed and assaying it for ATP. The assay for ATP may be performed by colorimetric assay or, as preferred, luminometry.

A further preferred method using a capture column which comprises binding agent, eg antibody, immobilised on solid substrate, eg beads, and passes the sample and various reagents down the column sequentially to achieve output of synthesised ATP which is measured and related to presence of the antibody target material.

In all cases, the amount of ADP with which the sample is mixed is preferably sufficient to provide an ADP concentration in the mixture in excess of 0.005mM, more preferably in excess of 0.01mM and most preferably in excess of 0.08mM. A particularly preferred amount of ADP in the conversion step mixture is about 0.1mM. This may depend upon the purity of the ADP: high levels of contamination with ATP restrict higher concentrations being used. The ranges that would be practically useful for ADP are from approximately 10mM to approximately 0.1 $\mu$ M. For the preferred concentrations of ADP set out above, the preferred concentration of magnesium ions in the suspension or solution during conversion of ADP to ATP is 1mM or more, more preferably 5mM or more and most preferably 10mM or more. The magnesium ions may be provided in the form of any magnesium salt, but preferably as magnesium acetate. The ranges that would be practically useful for Mg<sup>2+</sup> are from approximately 0.1mM to approximately 25mM. The amount of Mg<sup>2+</sup> present may depend, amongst other things, on ADP concentration and amount of chelator (e.g. EDTA) present.

A further preferred format of the present invention adds the luciferin/luciferase luminometry reagents to the sample at the beginning of the incubation, preferably as a single reagent with the ADP and magnesium ion source. This format requires the provision of luciferase reagent of high purity in terms of removal of adenylate kinase during its production. In formats of the invention where all the reagents are included at the start of the conversion of ADP to ATP in this manner, and/or where luminometer counting is continued after luciferin/luciferase addition where that is a separate step, magnesium may be provided by the



luciferin/luciferase reagent. However, due to binding of magnesium ions by luciferase and EDTA it is necessary that the amount of magnesium ions is positively ensured by prior experiment or calculation. It will be realised by those skilled in the art that the optimal amount of magnesium salt to be added to a given ADP, sample and luciferin/luciferase mixture will be readily determinable by routine experiment using a sample containing a known amount of bacteria, eg E. coli, whereby maximal signals are obtained.

As magnesium ions can cause instability in ADP (in terms of allowing contaminating adenylate kinase to prematurely convert it to ATP) it is preferred not to keep them in solution together prior to use, preferably they are brought together just prior to use or in the ADP conversion step. As magnesium ions are required for the activity of adenylate kinase it may be preferred to mix these and the sample together before adding ADP. Where the reagents are to be kept together it is preferred that they are kept in freeze dried form to avoid any unstabilising effects.

As stated above, adenosine triphosphate (ATP) is preferably detected by use of the luciferin/luciferase system to provide a photometrically detectable signal indicative of the amount of ATP in the sample. Luciferin/luciferase preparations and methods for their use in assaying ATP will be well known to those skilled in the art and are commercially available (eg see Brolin et al). A typical formulation contains eg 0.1 to 10mg/litre luciferase, 15 to 1000  $\mu\text{mol/litre}$ , preferably 15 to 100  $\mu\text{mol/litre}$  (eg  $\sim 36 \mu\text{mol/litre}$ ) D-luciferin, and agents such as  $\text{MgCl}_2$  (2.5-25mmole), EDTA, BSA, and pH7 buffer (see eg EP 054676) more typically pH7.8.

For single reagent use with adenylate kinase testing methods as described herein it is preferred that the pH is adjusted to that which is optimal for both enzymes, ie a compromise, in order that counting might continue while converting ADP to ATP. This may be determined by routine experiment using known bacterial numbers in a sample.

The sample, ADP and magnesium ion source may be mixed in any buffer providing a pH suitable for the adenylate kinase reaction: no other reagents are necessary. Thus any buffer providing a pH of between 5.5 and 8.5 might be used, with optimal pH lying between pH6

and 7, preferably pH6.5. Examples of suitable buffers include Tris and phosphate buffers. Most suitably the sample is collected and/or diluted in such a buffer in preparation for carrying out the method of the invention.

As with any amplified assay, the sensitivity of the adenylate kinase assay of the present invention is limited by the purity of the reagents. In this case the significant contaminants are ATP in the ADP substrate and adenylate kinase in the luciferase preparation. For use as a sensitive assay for micro-organisms, particularly where these may be potentially harmful and need detecting in low numbers, it is necessary that the purity of each of the reagents be as high as possible with respect to the substance with which it is to react in the assay.

Using a preferred Econopaq Q strong anion exchange gel cartridge (BioRad) equilibrated with 20mM potassium phosphate at pH4.6 and eluting with steps of  $KP_i$  (potassium phosphate) concentration up to 400mM. ADP was found to be eluted as a coherent peak with ATP eluting after it. In this manner ADP with a molar % ATP upper limit of  $2 \times 10^{-8}$  was obtainable. The most pure ADP the applicants are aware of from the literature is 0.001% (see Shutenko et al, as above) thus the present invention provides ADP for use in the method of the present invention that has less than 0.001 molar % ATP, more preferably  $2 \times 10^{-8}$  molar % or less.

With regard to the second problem, adenylate kinase, as an essential "housekeeping" enzyme, is present in virtually all organisms and is generally present in luciferase preparations. It may only be a minor contaminant, but since the aim is to measure very low adenylate kinase levels in samples, its presence in the luciferase may be a limiting factor.

The molecular weights of luciferase and adenylate kinase are significantly different, being 61kD and 21kD respectively. Furthermore luciferase is a membrane associated protein and therefore relatively hydrophobic, whereas adenylate kinase occurs as a soluble enzyme. It is thus possible to remove adenylate kinase from luciferase preparations by, eg size exclusion chromatography, reverse phase chromatography, or both. Alternatively or in addition to this, the problem of adenylate kinase contamination of luciferase can be avoided by adding the

bioluminescent reagents (luciferase and luciferin) just before or as measurements are taken so that any contaminating adenylate kinase does not have the time to produce a significant effect.

Suitable methods for purifying luciferase use column chromatography fractionation with a low porosity gel, eg Sephadex G-25 (see Nielsen and Rasmussen, *Acta Chemica Scandinavica* 22 (1968) p1757-1762; use of Sephadex and Sepharose columns (eg Blue Sepharose) in series and by SDS electrophoresis (see Devine et al, *Biochimica et Biophysica Acta* 1172 (1993) 121-132) or aging for a period at elevated ambient temperature.

A source of adenylate kinase free BSA, a component of commercial luciferase/luciferin preparations, is the chemically treated reagent acetylated-BSA, available from Sigma and BDH. It will be realised by those skilled in the art that other chemically treated BSAs will also be suitable.

In order to render all the adenylate kinase associated with a target micro-organism available to the ADP, magnesium ions and luciferase/luciferin assay reagents of the invention it will be necessary to disrupt them such that intracellular material is released or otherwise exposed to the reagents. Such disruption might be carried out using mechanical means such as an ultrasonic generator, by use of osmotic shock optionally in association with cold shock or such agents as lysozyme or, more conveniently, by use of detergents. Such detergents are commercially available and commonly referred to as 'extractants'. Typical extractants include generic cationic detergents such as CTAB (Cetyl Trimethyl Ammonium Bromide), and proprietary agents such as Enzymatics ATP releasing agent, Biotrace XM extractant (available from Biotrace, Bridgend UK), Celsis UK cationic extractants and Lumac NRM (nucleotide releasing agent available from Lumac BV, Holland). When using CTAB a convenient preparation will include 0.01 to 1% CTAB in water, eg 0.2%, but other concentrations may occur to those skilled in the art.

Thus before adding ADP and luciferase/luciferin reagent(s) to an assay sample suspected of containing micro-organisms it is preferred to disrupt these to render their intracellular

contents accessible to luminometry reagents by use of disrupting agent. If it is desired to distinguish between target cells and cells such as those of fungal spores it is possible to run two separate assays treating one with a nonionic detergent capable of disrupting only those spore and multi-cellular 'somatic' animal cells (eg Triton X-100 available from Sigma) and the other with cationic detergent 'extractants' detailed above for disrupting all cells. It is possible to carry out these assays on the same sample if an ATPase such as apyrase followed by a protease is added between detergent/luciferase/measurement cycles; one cycle using nonionic and other cationic detergent in a first cycle step.

The effect of extractant upon the luciferase/luciferin system is known to be important (see e.g. Simpson et al (1991) J Biolumin Chemilumin 6(2) pp97-106; with cationic detergents being known to potentiate the reaction but to cause gradual inactivation of luciferase, anionic detergent inhibiting the reaction and nonionic and zwitterionic detergents being known to potentiate over a wide range. A mixture of 0.15% cationic detergent together with 0.25% tertiary diamine surfactant (obtained from Celsis, Cambridge, UK) was found to be satisfactory for present purposes, but those skilled in the art will have no problem screening for other 'extractants' that yield an optimal mix of adenylate kinase and luciferase activity when copresent in the same solution. Typically a range of detergent concentrations of approximately 0.05% to 1.0% may be used.

The light given off from the mixture after all the essential steps are complete, ie ADP conversion to ATP and subsequent action of luciferase upon luciferin, may be measured by residence of the sample volume, eg luminometer tube, within a light detector immediately after or simultaneously with addition of the luciferase and luciferin or other agents which enable the essential steps to proceed.

In a second aspect of the present invention there is provided a test kit comprising the essential reagents required for the method of the invention, ie immobilised capture agent, adenosine diphosphate and preferably a source of magnesium ions and preferably luciferase and luciferin. Preferably the kit includes all these reagents, with the luciferase and luciferin being provided as a single reagent solution, with a detergent reagent in the kit suitable for disrupting the target cells for which the assay is intended. Usually for assaying micro-

organisms only cationic detergent is needed, whereas if fungal spores and somatic cells are likely to be significant then a further nonionic detergent reagent might be included to assess their numbers. The kit is in the form of a single package preferably including instructions as to how to perform the method of the invention; the reagents being provided in containers and being of strength suitable for direct use or after dilution.

A preferred test kit of the invention comprises immobilised antibody, in the form of loose beads, a column filled with beads or a coated microtitre well, ADP reagent which is of purity higher than 99.999%, and a luciferase/luciferin reagent, including BSA, that is substantially free of adenylate kinase activity. Alternatively the luciferase/luciferin ratio used, reflected in the kit instructions for use and/or in their relative concentrations, is such that the luciferase is capable of acting upon the luciferin substrate sufficiently quickly such that any luciferase associated adenylate kinase produces ATP after the initial emission is finished: thus micro-organism derived adenylate kinase will be indicated by a flash kinetic reaction and contaminant ATP by a glow.

Further provided by the present invention is apparatus for performance of the method of the invention comprising a reaction chamber in which the immobilised capture agent is interacted with sample in use, this chamber having inlet and outlet means for supply of reagents in sequential fashion such as to carry out the binding, extractant and ADP addition steps of the assay of the invention, and being connected with a source of luciferase/luciferin reagent to a luminometer flow cell such that on completion of all of these steps, generated ATP can be directly measured by correlation with the amount of light emitted. Preferred reaction chambers of the apparatus of the present invention include:

- (a) A reaction vessel located within the range of an electrically operable magnet such that magnetic beads suspended in the vessel in a reaction liquid can be immobilised as required for change of reagents, eg under influence of pump means, or

- (b) a reactor column comprising conventional capture agent support material. eg latex beads. coated with capture agent.

The methods, apparatus, reagents and kits of the present invention will now be illustrated by way of example only with reference to the following non-limiting Examples and Figures. Further embodiments will occur to those skilled in the art in the light of these.

## FIGURES

- Figure 1: Shows a diagrammatic representation of an apparatus for performance of the method of the invention using an automated flow system with immobilisation of capture agent on magnetic beads and using a selectively magnetised magnet to trap them.
- Figure 2: Shows a diagrammatic representation of an apparatus for performance of the method of the invention using an automated flow system with immobilisation of capture agent on a reactor column.
- Figure 3: Illustrates in graphical form Adenylate Kinase Assays for low numbers of *E. coli* cells
- Figure 4: Illustrates in bar chart form Specific Assay for *E. coli* using magnetic beads for capture and adenylate kinase for detection

Example 1: Assay of *E. coli* using apparatus of figure 1

A liquid sample containing *E. coli* for assay is supplied from a sample source (1) via a five-way valve (2), peristaltic tubing (3) and reversible pump (4) to a reaction vessel (5) containing antibodies specific to *E. coli* that have been immobilised upon Dynal magnetic beads by conventional covalent coupling. The beads and sample are stirred together for a capture period, eg 1 to 30 minutes. using stirrer (6). magnet (7) energised to immobilise the beads. and sample liquid removed to waste (8) via the reversible pump (4) and valve (2). The beads are washed by supply of wash buffer from source (9), deenergisation of magnet (7), operation of stirrer (6), energisation of magnet (7) and removal of buffer to waste.

ADP substrate (>99.999% pure with respect to ATP), magnesium acetate and extractant reagent (0.15% cationic detergent and 0.25% tertiary diamine per final volume) is supplied from source (10) in sufficient quantity to provide 0.1mM ADP and 10mM magnesium ions

in the reaction vessel, the magnet deenergised and stirrer operated and extraction/ADP conversion allowed to proceed for a set period between of 1 or 5 minutes before the stirrer is stopped. the magnet energised and the liquid removed to the luminometer flow cell (11) using the peristaltic tubing (3) and reversible pumps (4) and (12) while simultaneously mixing it with an effective volume of luciferase/luciferin reagent of depleted adenylate kinase content from source (13). Using an adenylate kinase modified Celsis LDR reagent of otherwise standard amounts of active ingredients this volume is about one half of the volume of the sample. Light emitted in the flow cell is related to the amount of E. coli captured by reference to standard curves obtained by performance of the assay with known numbers of cells.

Regeneration of the reaction vessel magnetic beads is carried out by pumping used beads to waste and supplying new ones from source (14). or using a reagent or solution which dissociates the sample from the beads so that the beads are regenerated. for example if the regeneration is from antibodies then ~0.1M HCl may be used.



Example 2: Assay of E. coli using apparatus of figure 2

Assay is performed as per Example 1 but with the vessel (5), magnet (6) and stirrer (7) replaced by a reactor column in-line with a luminometer flow cell and supplied with the reagents from sources annotated as before. Use is made of three two way valves (2) rather than a single five way valve and the pumps are not reversible. The source of sample is derived directly from a hydrocyclone as described in copending UK patent application GB9405392.3.

It will be realised that a five way valve arrangement of Example 1 may be used with such reactor column method, and that the in-line three two way valves may be used with the reaction vessel and stirrer of Example 2. Similarly the assay steps may readily be carried out by manual operation of the magnet and manual addition of reagents.

✱

✱

**CLAIMS**

1. A method for determining the presence and/or amount of a micro-organism and/or its intracellular material present in a sample characterised in that it comprises:

- (a) exposing the sample to a specific binding agent that has been immobilised upon a solid substrate, the specific binding agent being capable of binding to the micro-organism or its intracellular material such that it becomes associated with the solid substrate,
- (b) exposing the solid substrate to an agent capable of making adenylate kinase associated with the micro-organism and/or its intracellular material accessible to solutions applied to the substrate,
- (c) applying a solution containing adenosine diphosphate (ADP) to the substrate under conditions whereby adenosine triphosphate (ATP) may be produced by any adenylate kinase present,
- (d) measuring the amount of adenosine triphosphate (ATP) produced and relating that to the presence and/or amount of micro-organism or intracellular contents.

2. A method as claimed in claim 1 wherein step (d) is carried out using an assay that includes a colour forming reaction.

3. A method as claimed in claim 1 wherein step (d) is carried out by use of luciferase/luciferin reagent to produce light proportional to the amount of ATP produced, and that is detected using a luminometer.

4. A method as claimed in claim 1, 2 or 3 wherein the conditions used in step (c) include presence of magnesium ions at a concentration sufficient to allow maximal conversion of ADP to ATP.
5. A method as claimed in claim 4 wherein steps (b) and (c) are carried out by adding extractant, ADP and magnesium ions to the sample and incubating the mixture for a predetermined period to effect conversion of ADP to ATP.
6. A method as claimed in any one of the preceding claims wherein the capture step is carried out using immobilised antibodies which are specific to a genus, species or class of micro-organism or binding agents specific to particular materials on the cell walls of many different types of micro-organism.
7. A method as claimed in claim 6 wherein the capture agent is an antibody linked to the solid substrate using covalent coupling or streptavidin/biotin interaction.
8. A method as claimed in any one of the preceding claims wherein the solid substrate is capable of being held by a magnetic field.
9. A method as claimed in claim 8 wherein the capture step is carried out by adding magnetic beads with antibody immobilised thereon to a vessel, adding the sample to be assayed as a solution or suspension and stirring it, immobilising the beads with any captured micro-organisms and/or material using a magnetic field, removing residual solution or suspension, adding ADP substrate and extractant solution or solutions for rendering the adenylylate kinase accessible to ADP solution, removing the magnetic field and stirring the beads in the substrate solution, immobilising the beads by reapplication of the magnetic field, removing solution containing the ADP, extractant and any ATP formed and assaying that for ATP.
10. A method as claimed in any one of the claims 1 to 7 wherein the capture agent is retained within a column.

11. A method as claimed in claim 10 wherein the agent is retained on beads held within the column.
12. A method as claimed in claim 11 wherein the sample and the assay reagents are passed down the column sequentially to achieve output of synthesised ATP which is measured and related to presence of the capture agent target material.
13. A method as claimed in any one of the preceding claims wherein the amount of ADP to which the bound sample is exposed is sufficient to provide an ADP concentration of in excess of 0.005mM.
14. A method as claimed in claim 13 wherein the amount of ADP is sufficient to provide an ADP concentration of about 0.1mM.
15. A method as claimed in claim 13 wherein the concentration of magnesium ions to which the bound sample is exposed is 1mM or more.
16. A method as claimed in claim 15 wherein the magnesium ion concentration is 10mM or more.
17. A method as claimed in any one of claims 1 to 16 wherein the step (b) is carried out by adding a reagent comprising a cationic detergent.
18. A method as claimed in claim 17 wherein the reagent comprises a tertiary diamine.
19. A test kit comprising immobilised specific capture agent and adenosine diphosphate reagent.
20. A test kit as claimed in claim 19 further comprising a source of magnesium ions and/or luciferase and luciferin.

21. A test kit as claimed in claim 20 comprising an antibody immobilised upon a solid support provided in the form of loose beads, a column filled with beads or a coated microtitre well; ADP reagent which is of purity higher than 99.99%, and a luciferase/luciferin reagent, including BSA, that is substantially free of adenylyate kinase activity.
22. A test kit comprising immobilised specific capture agent, the specific capture agent being capable of binding to a micro-organism or its intracellular material and further comprising adenosine diphosphate reagent.
23. An apparatus for performing a method as claimed in any one of the claims 1 to 18 comprising a reaction chamber in which immobilised capture agent is interacted with sample in use, this chamber having inlet and outlet means for supply of reagents in sequential fashion such as to carry out binding, extractant and ADP addition steps, and being connected with a source of luciferase/luciferin reagent to a luminometer flow cell such that on completion of all of these steps, generated ATP can be directly measured by correlation with the amount of light emitted.
24. An apparatus as claimed in claim 23 wherein the reaction chamber comprises:
- (a) a reaction vessel located within the range of an electrically operable magnet such that magnetic beads suspended in the vessel in a reaction liquid can be immobilised as required for change of reagents,
  - (b) a reactor column comprising conventional capture agent support material coated with capture agent.
25. An apparatus according to either of claims 22 and 23 wherein the capture agent is a specific capture agent.

Fig.1.






Fig.2.




SUBSTITUTE SHEET (RULE 26)

Fig.3.



SUBSTITUTE SHEET (RULE 26)

Fig.4.



SUBSTITUTE SHEET (RULE 26)



## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 95/01643

## A. CLASSIFICATION OF SUBJECT MATTER

C 12 Q 1/04, C 12 Q 1/06, G 01 N 33/569, G 01 N 33/543,  
C 12 Q 1/48, C 12 Q 1/66

According to International Patent Classification (IPC) or to both national classification and IPC 6

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C 12 Q, G 01 N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category \* Citation of document, with indication, where appropriate, of the relevant passages

Relevant to claim No.

A EP, A, 0 217 583  
(VXR INC.) 08 April 1987  
(08.04.87),  
claims 1-7, 16-19, 29-33, 42.

1,  
8-11

P, A WO, A, 94/17 202  
(THE SECRETARY OF STATE FOR  
DEFENCE IN HER BRITANNIC  
MAJESTY'S GOVERNMENT OF THE  
UNITED KINGDOM OF GREAT  
BRITAIN AND NORTHERN IRELAND)  
04 August 1994 (04.08.94),  
the whole document.

1-7,  
13-24

A CHEMICAL ABSTRACTS, vol. 93,  
no. 5, issued 1980, August 4,  
(Columbus, Ohio, USA),  
S.E. BROLIN et al.: "Firefly  
luciferase assay of adenylate

1-5,  
13-16

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \* "A" document defining the general state of the art which is not considered to be of particular relevance
- \* "E" earlier document but published on or after the international filing date
- \* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \* "O" document referring to an oral disclosure, use, exhibition or other means
- \* "P" document published prior to the international filing date but later than the priority date claimed

- \* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \* "&" document member of the same patent family

Date of the actual completion of the international search  
16 October 1995

Date of mailing of the international search report

15. 11. 95

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

SCHNASS e.h.

## INTERNATIONAL SEARCH REPORT

-2-

International Application No

PCT/GB 95/01643

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	<p>kinase in insulin and glucagon-producing cells" page 370, no. 40 093j; &amp; Proc.-Int. Symp. Anal. Appl. Biolumin. Chemilumin. 1978 (Pub. 1979), 458-66. -----</p>	

## ANHANG

zum internationalen Recherchen-  
bericht über die internationale  
Patentanmeldung Nr.

## ANNEX

to the International Search  
Report to the International Patent  
Application No.

## ANNEXE

au rapport de recherche inter-  
national relatif à la demande de brevet  
international n°

FCT/GB 95/01643 SAE 113558

In diesem Anhang sind die Mitglieder der Patentfamilien der im obengenannten internationalen Recherchenbericht angeführten Patentedokumente angegeben. Diese Angaben dienen nur zur Unter-  
richtung und erfolgen ohne Gewähr.

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The Office is in no way liable for these particulars which are given merely for the purpose of information.

La présente annexe indique les  
mémoires de la famille de brevets  
relatifs aux documents de brevets cités  
dans le rapport de recherche inter-  
national visée ci-dessus. Les renseigne-  
ments fournis sont données à titre indica-  
tif et n'engagent pas la responsabilité  
de l'Office.

Im Recherchenbericht angeführtes Patentedokument Patent document cited in search report Document de brevet cité dans le rapport de recherche		Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
EP A1	217583	08-04-87	A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13 A14 A15 A16 A17 A18 A19 A20 A21 A22 A23 A24 A25 A26 A27 A28 A29 A30 A31 A32 A33 A34 A35 A36 A37 A38 A39 A40 A41 A42 A43 A44 A45 A46 A47 A48 A49 A50 A51 A52 A53 A54 A55 A56 A57 A58 A59 A60 A61 A62 A63 A64 A65 A66 A67 A68 A69 A70 A71 A72 A73 A74 A75 A76 A77 A78 A79 A80 A81 A82 A83 A84 A85 A86 A87 A88 A89 A90 A91 A92 A93 A94 A95 A96 A97 A98 A99 A100 A101 A102 A103 A104 A105 A106 A107 A108 A109 A110 A111 A112 A113 A114 A115 A116 A117 A118 A119 A120 A121 A122 A123 A124 A125 A126 A127 A128 A129 A130 A131 A132 A133 A134 A135 A136 A137 A138 A139 A140 A141 A142 A143 A144 A145 A146 A147 A148 A149 A150 A151 A152 A153 A154 A155 A156 A157 A158 A159 A160 A161 A162 A163 A164 A165 A166 A167 A168 A169 A170 A171 A172 A173 A174 A175 A176 A177 A178 A179 A180 A181 A182 A183 A184 A185 A186 A187 A188 A189 A190 A191 A192 A193 A194 A195 A196 A197 A198 A199 A200 A201 A202 A203 A204 A205 A206 A207 A208 A209 A210 A211 A212 A213 A214 A215 A216 A217 A218 A219 A220 A221 A222 A223 A224 A225 A226 A227 A228 A229 A230 A231 A232 A233 A234 A235 A236 A237 A238 A239 A240 A241 A242 A243 A244 A245 A246 A247 A248 A249 A250 A251 A252 A253 A254 A255 A256 A257 A258 A259 A260 A261 A262 A263 A264 A265 A266 A267 A268 A269 A270 A271 A272 A273 A274 A275 A276 A277 A278 A279 A280 A281 A282 A283 A284 A285 A286 A287 A288 A289 A290 A291 A292 A293 A294 A295 A296 A297 A298 A299 A300 A301 A302 A303 A304 A305 A306 A307 A308 A309 A310 A311 A312 A313 A314 A315 A316 A317 A318 A319 A320 A321 A322 A323 A324 A325 A326 A327 A328 A329 A330 A331 A332 A333 A334 A335 A336 A337 A338 A339 A340 A341 A342 A343 A344 A345 A346 A347 A348 A349 A350 A351 A352 A353 A354 A355 A356 A357 A358 A359 A360 A361 A362 A363 A364 A365 A366 A367 A368 A369 A370 A371 A372 A373 A374 A375 A376 A377 A378 A379 A380 A381 A382 A383 A384 A385 A386 A387 A388 A389 A390 A391 A392 A393 A394 A395 A396 A397 A398 A399 A400 A401 A402 A403 A404 A405 A406 A407 A408 A409 A410 A411 A412 A413 A414 A415 A416 A417 A418 A419 A420 A421 A422 A423 A424 A425 A426 A427 A428 A429 A430 A431 A432 A433 A434 A435 A436 A437 A438 A439 A440 A441 A442 A443 A444 A445 A446 A447 A448 A449 A450 A451 A452 A453 A454 A455 A456 A457 A458 A459 A460 A461 A462 A463 A464 A465 A466 A467 A468 A469 A470 A471 A472 A473 A474 A475 A476 A477 A478 A479 A480 A481 A482 A483 A484 A485 A486 A487 A488 A489 A490 A491 A492 A493 A494 A495 A496 A497 A498 A499 A500 A501 A502 A503 A504 A505 A506 A507 A508 A509 A510 A511 A512 A513 A514 A515 A516 A517 A518 A519 A520 A521 A522 A523 A524 A525 A526 A527 A528 A529 A530 A531 A532 A533 A534 A535 A536 A537 A538 A539 A540 A541 A542 A543 A544 A545 A546 A547 A548 A549 A550 A551 A552 A553 A554 A555 A556 A557 A558 A559 A560 A561 A562 A563 A564 A565 A566 A567 A568 A569 A570 A571 A572 A573 A574 A575 A576 A577 A578 A579 A580 A581 A582 A583 A584 A585 A586 A587 A588 A589 A590 A591 A592 A593 A594 A595 A596 A597 A598 A599 A600 A601 A602 A603 A604 A605 A606 A607 A608 A609 A610 A611 A612 A613 A614 A615 A616 A617 A618 A619 A620 A621 A622 A623 A624 A625 A626 A627 A628 A629 A630 A631 A632 A633 A634 A635 A636 A637 A638 A639 A640 A641 A642 A643 A644 A645 A646 A647 A648 A649 A650 A651 A652 A653 A654 A655 A656 A657 A658 A659 A660 A661 A662 A663 A664 A665 A666 A667 A668 A669 A670 A671 A672 A673 A674 A675 A676 A677 A678 A679 A680 A681 A682 A683 A684 A685 A686 A687 A688 A689 A690 A691 A692 A693 A694 A695 A696 A697 A698 A699 A700 A701 A702 A703 A704 A705 A706 A707 A708 A709 A710 A711 A712 A713 A714 A715 A716 A717 A718 A719 A720 A721 A722 A723 A724 A725 A726 A727 A728 A729 A730 A731 A732 A733 A734 A735 A736 A737 A738 A739 A740 A741 A742 A743 A744 A745 A746 A747 A748 A749 A750 A751 A752 A753 A754 A755 A756 A757 A758 A759 A760 A761 A762 A763 A764 A765 A766 A767 A768 A769 A770 A771 A772 A773 A774 A775 A776 A777 A778 A779 A780 A781 A782 A783 A784 A785 A786 A787 A788 A789 A790 A791 A792 A793 A794 A795 A796 A797 A798 A799 A800 A801 A802 A803 A804 A805 A806 A807 A808 A809 A810 A811 A812 A813 A814 A815 A816 A817 A818 A819 A820 A821 A822 A823 A824 A825 A826 A827 A828 A829 A830 A831 A832 A833 A834 A835 A836 A837 A838 A839 A840 A841 A842 A843 A844 A845 A846 A847 A848 A849 A850 A851 A852 A853 A854 A855 A856 A857 A858 A859 A860 A861 A862 A863 A864 A865 A866 A867 A868 A869 A870 A871 A872 A873 A874 A875 A876 A877 A878 A879 A880 A881 A882 A883 A884 A885 A886 A887 A888 A889 A890 A891 A892 A893 A894 A895 A896 A897 A898 A899 A900 A901 A902 A903 A904 A905 A906 A907 A908 A909 A910 A911 A912 A913 A914 A915 A916 A917 A918 A919 A920 A921 A922 A923 A924 A925 A926 A927 A928 A929 A930 A931 A932 A933 A934 A935 A936 A937 A938 A939 A940 A941 A942 A943 A944 A945 A946 A947 A948 A949 A950 A951 A952 A953 A954 A955 A956 A957 A958 A959 A960 A961 A962 A963 A964 A965 A966 A967 A968 A969 A970 A971 A972 A973 A974 A975 A976 A977 A978 A979 A980 A981 A982 A983 A984 A985 A986 A987 A988 A989 A990 A991 A992 A993 A994 A995 A996 A997 A998 A999 A1000 A1001 A1002 A1003 A1004 A1005 A1006 A1007 A1008 A1009 A1010 A1011 A1012 A1013 A1014 A1015 A1016 A1017 A1018 A1019 A1020 A1021 A1022 A1023 A1024 A1025 A1026 A1027 A1028 A1029 A1030 A1031 A1032 A1033 A1034 A1035 A1036 A1037 A1038 A1039 A1040 A1041 A1042 A1043 A1044 A1045 A1046 A1047 A1048 A1049 A1050 A1051 A1052 A1053 A1054 A1055 A1056 A1057 A1058 A1059 A1060 A1061 A1062 A1063 A1064 A1065 A1066 A1067 A1068 A1069 A1070 A1071 A1072 A1073 A1074 A1075 A1076 A1077 A1078 A1079 A1080 A1081 A1082 A1083 A1084 A1085 A1086 A1087 A1088 A1089 A1090 A1091 A1092 A1093 A1094 A1095 A1096 A1097 A1098 A1099 A1100 A1101 A1102 A1103 A1104 A1105 A1106 A1107 A1108 A1109 A1110 A1111 A1112 A1113 A1114 A1115 A1116 A1117 A1118 A1119 A1120 A1121 A1122 A1123 A1124 A1125 A1126 A1127 A1128 A1129 A1130 A1131 A1132 A1133 A1134 A1135 A1136 A1137 A1138 A1139 A1140 A1141 A1142 A1143 A1144 A1145 A1146 A1147 A1148 A1149 A1150 A1151 A1152 A1153 A1154 A1155 A1156 A1157 A1158 A1159 A1160 A1161 A1162 A1163 A1164 A1165 A1166 A1167 A1168 A1169 A1170 A1171 A1172 A1173 A1174 A1175 A1176 A1177 A1178 A1179 A1180 A1181 A1182 A1183 A1184 A1185 A1186 A1187 A1188 A1189 A1190 A1191 A1192 A1193 A1194 A1195 A1196 A1197 A1198 A1199 A1200 A1201 A1202 A1203 A1204 A1205 A1206 A1207 A1208 A1209 A1210 A1211 A1212 A1213 A1214 A1215 A1216 A1217 A1218 A1219 A1220 A1221 A1222 A1223 A1224 A1225 A1226 A1227 A1228 A1229 A1230 A1231 A1232 A1233 A1234 A1235 A1236 A1237 A1238 A1239 A1240 A1241 A1242 A1243 A1244 A1245 A1246 A1247 A1248 A1249 A1250 A1251 A1252 A1253 A1254 A1255 A1256 A1257 A1258 A1259 A1260 A1261 A1262 A1263 A1264 A1265 A1266 A1267 A1268 A1269 A1270 A1271 A1272 A1273 A1274 A1275 A1276 A1277 A1278 A1279 A1280 A1281 A1282 A1283 A1284 A1285 A1286 A1287 A1288 A1289 A1290 A1291 A1292 A1293 A1294 A1295 A1296 A1297 A1298 A1299 A1300 A1301 A1302 A1303 A1304 A1305 A1306 A1307 A1308 A1309 A1310 A1311 A1312 A1313 A1314 A1315 A1316 A1317 A1318 A1319 A1320 A1321 A1322 A1323 A1324 A1325 A1326 A1327 A1328 A1329 A1330 A1331 A1332 A1333 A1334 A1335 A1336 A1337 A1338 A1339 A1340 A1341 A1342 A1343 A1344 A1345 A1346 A1347 A1348 A1349 A1350 A1351 A1352 A1353 A1354 A1355 A1356 A1357 A1358 A1359 A1360 A1361 A1362 A1363 A1364 A1365 A1366 A1367 A1368 A1369 A1370 A1371 A1372 A1373 A1374 A1375 A1376 A1377 A1378 A1379 A1380 A1381 A1382 A1383 A1384 A1385 A1386 A1387 A1388 A1389 A1390 A1391 A1392 A1393 A1394 A1395 A1396 A1397 A1398 A1399 A1400 A1401 A1402 A1403 A1404 A1405 A1406 A1407 A1408 A1409 A1410 A1411 A1412 A1413 A1414 A1415 A1416 A1417 A1418 A1419 A1420 A1421 A1422 A1423 A1424 A1425 A1426 A1427 A1428 A1429 A1430 A1431 A1432 A1433 A1434 A1435 A1436 A1437 A1438 A1439 A1440 A1441 A1442 A1443 A1444 A1445 A1446 A1447 A1448 A1449 A1450 A1451 A1452 A1453 A1454 A1455 A1456 A1457 A1458 A1459 A1460 A1461 A1462 A1463 A1464 A1465 A1466 A1467 A1468 A1469 A1470 A1471 A1472 A1473 A1474 A1475 A1476 A1477 A1478 A1479 A1480 A1481 A1482 A1483 A1484 A1485 A1486 A1487 A1488 A1489 A1490 A1491 A1492 A1493 A1494 A1495 A1496 A1497 A1498 A1499 A1500 A1501 A1502 A1503 A1504 A1505 A1506 A1507 A1508 A1509 A1510 A1511 A1512 A1513 A1514 A1515 A1516 A1517 A1518 A1519 A1520 A1521 A1522 A1523 A1524 A1525 A1526 A1527 A1528 A1529 A1530 A1531 A1532 A1533 A1534 A1535 A1536 A1537 A1538 A1539 A1540 A1541 A1542 A1543 A1544 A1545 A1546 A1547 A1548 A1549 A1550 A1551 A1552 A1553 A1554 A1555 A1556 A1557 A1558 A1559 A1560 A1561 A1562 A1563 A1564 A1565 A1566 A1567 A1568 A1569 A1570 A1571 A1572 A1573 A1574 A1575 A1576 A1577 A1578 A1579 A1580 A1581 A1582 A1583 A1584 A1585 A1586 A1587 A1588 A1589 A1590 A1591 A1592 A1593 A1594 A1595 A1596 A1597 A1598 A1599 A1600 A1601 A1602 A1603 A1604 A1605 A1606 A1607 A1608 A1609 A1610 A1611 A1612 A1613 A1614 A1615 A1616 A1617 A1618 A1619 A1620 A1621 A1622 A1623 A1624 A1625 A1626 A1627 A1628 A1629 A1630 A1631 A1632 A1633 A1634 A1635 A1636 A1637 A1638 A1639 A1640 A1641 A1642 A1643 A1644 A1645 A1646 A1647 A1648 A1649 A1650 A1651 A1652 A1653 A1654 A1655 A1656 A1657 A1658 A1659 A1660 A1661 A1662 A1663 A1664 A1665 A1666 A1667 A1668 A1669 A1670 A1671 A1672 A1673 A1674 A1675 A1676 A1677 A1678 A1679 A1680 A1681 A1682 A1683 A1684 A1685 A1686 A1687 A1688 A1689 A1690 A1691 A1692 A1693 A1694 A1695 A1696 A1697 A1698 A1699 A1700 A1701 A1702 A1703 A1704 A1705 A1706 A1707 A1708 A1709 A1710 A1711 A1712 A1713 A1714 A1715 A1716 A1717 A1718 A1719 A1720 A1721 A1722 A1723 A1724 A1725 A1726 A1727 A1728 A1729 A1730 A1731 A1732 A1733 A1734 A1735 A1736 A1737 A1738 A1739 A1740 A1741 A1742 A1743 A1744 A1745 A1746 A1747 A1748 A1749 A1750 A1751 A1752 A1753 A1754 A1755 A1756 A1757 A1758 A1759 A1760 A1761 A1762 A1763 A1764 A1765 A1766 A1767 A1768 A1769 A1770 A1771 A1772 A1773 A1774 A1775 A1776 A1777 A1778 A1779 A1780 A1781 A1782 A1783 A1784 A1785 A1786 A1787 A1788 A1789 A1790 A1791 A1792 A1793 A1794 A1795 A1796 A1797 A1798 A1799 A1800 A1801 A1802 A1803 A1804 A1805 A1806 A1807 A1808 A1809 A1810 A1811 A1812 A1813 A1814 A1815 A1816 A1817 A1818 A1819 A1820 A1821 A1822 A1823 A1824 A1825 A1826 A1827 A1828 A1829 A1830 A1831 A1832 A1833 A1834 A1835 A1836 A1837 A1838 A1839 A1840 A1841 A1842 A1843 A1844 A1845 A1846 A1847 A1848 A1849 A1850 A1851 A1852 A1853 A1854 A1855 A1856 A1857 A1858 A1859 A1860 A1861 A1862 A1863 A1864 A1865 A1866 A1867 A1868 A1869 A1870 A1871 A1872 A1873 A1874 A1875 A1876 A1877 A1878 A1879 A1880 A1881 A1882 A1883 A1884 A1885 A1886 A1887 A1888 A1889 A1890 A1891 A1892 A1893 A1894 A1895 A1896 A1897 A1898 A1899 A1900 A1901 A1902 	

**THIS PAGE BLANK (USPTO)**